Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy

Journal of Infection

Volumn 71, Issue 1, 2015, Pages 43-52

  Jeppesen, Catherine A ^a   Snape, Matthew D ^a   Robinson, Hannah ^a   Gossger, Nicoletta ^a   John, Tessa M ^a   Voysey, Merryn ^b   Ladhani, Shamez ^c   Okike, Ifeanyichukwu O ^d   Oeser, Clarissa ^d   Kent, Alison ^d   Oliver, Jennifer ^e   Taylor, Pippa ^e   Morales Aza, Begonia ^e   Clarke, Stuart C ^c,f   Casey, Michelle ^g   Martins, Filipa ^g   Kitchin, Nicholas R E ^h   Anderson, Annaliesa S ⁱ   Jones, Hal ⁱ   Jansen, Kathrin U ⁱ   Eiden, Joseph ⁱ   Pedneault, Louise ⁱ   Heath, Paul T ^d   Finn, Adam ^e   Faust, Saul N ^f,g   Pollard, Andrew J ^a   more..

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

ⁱ PFIZER INC   (United States)

Author keywords

Adolescents; Carriage; Factor H binding protein; Neisseria meningitidis; Serogroup

Indexed keywords

COMPLEMENT FACTOR H; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CARRIER; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; FEMALE; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MALE; NEISSERIA MENINGITIDIS; THROAT CULTURE; UNITED KINGDOM; AGGLUTINATION TEST; CLASSIFICATION; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; GREAT BRITAIN; HETEROZYGOTE; ISOLATION AND PURIFICATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MULTICENTER STUDY; PHARYNX; POLYMERASE CHAIN REACTION; SEROTYPE; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGGLUTINATION TESTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CARRIER STATE; CHILD; EPIDEMIOLOGIC STUDIES; GREAT BRITAIN; HUMANS; LONGITUDINAL STUDIES; MALE; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PHARYNX; POLYMERASE CHAIN REACTION; SEROGROUP; VACCINATION; YOUNG ADULT;

EID: 84930536884     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.02.006     Document Type: Article

References (35)

1. Gray S.J., Trotter C.L., Ramsay M.E., Guiver M., Fox A.J., Borrow R., et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006, 55(Pt 7):887-896.
2. Ladhani S.N., Flood J.S., Ramsay M.E., Campbell H., Gray S.J., Kaczmarski E.B., et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012, 30(24):3710-3716.
3. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
4. Public Health England. Invasive meningococcal infections (England and Wales), annual report for 2011/12. [cited 2013 24 September]. http://www.hpa.org.uk/hpr/archives/2013/hpr18-2213.pdf.
5. European Centre for Disease Prevention and Control Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data 2013, 168-171. ECDC, Stockholm.
6. Centers for Disease Control and Prevention Summary of Notifiable diseases - 2010. MMWR 2012, 59(53):43.
7. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(12):853-861.
8. Neal K.R., Nguyen-Van-Tam J.S., Jeffrey N., Slack R.C., Madeley R.J., Ait-Tahar K., et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000, 320(7238):846-849.
9. MacLennan J., Kafatos G., Neal K., Andrews N., Cameron J.C., Roberts R., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12(6):950-957.
10. Bidmos F.A., Neal K.R., Oldfield N.J., Turner D.P., Ala'Aldeen D.A., Bayliss C.D. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011, 49(2):506-512.
11. Yazdankhah S.P., Caugant D.A. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004, 53(Pt 9):821-832.
12. Maiden M.C., Ibarz-Pavón A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197(5):737-743.
13. ICH document Q2A Guidance for industry:validation of analytical procedures http://www.fda.gov/downloads/Drugs/Guidances/ucm073381.pdf.
14. ICH document Q2B Guidance for industry: validation of analytical procedures http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073384.pdf.
15. FDA document Guidance for industry: bioanalytical method validation http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
16. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):379-389.
17. Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
18. Read R.C., Baxter D., Chadwick D.R., Faust S.N., Finn A., Gordon S.B., et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014, 384(9960):2123-2131.
19. Maiden M.C., Stuart J.M. UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359(9320):1829-1831.
20. Ibarz-Pavón A.B., Maclennan J., Andrews N.J., Gray S.J., Urwin R., Clarke S.C., et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis 2011, 204(7):1046-1053.
21. Pollard A.J., Green C., Sadarangani M., Snape M.D. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Arch Dis Child 2013, 98(4):248-251.
22. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl. 1):S58-S67.
23. Ala'aldeen D.A., Oldfield N.J., Bidmos F.A., Abouseada N.M., Ahmed N.W., Turner D.P., et al. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis 2011, 17(9):1762-1763.
24. Public Health England. Invasive menigococcal disease by calendar year, age group and capsular group. England & Wales, 1998 to 2013 (provisional). Available at: [4 June 2014]. http://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-and-wales.
25. Ladhani S.N., Lucidarme J., Newbold L.S., Gray S.J., Carr A.D., Findlow J., et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis 2012, 18(1):63-70.
26. Harrison L.H. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010, 50(Suppl. 2):S37-S44.
27. Bröker M., Jacobsson S., Kuusi M., Pace D., Simfes M.J., Skoczynska A., et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother 2012, 8(12):1907-1911.
28. Soriano-Gabarró M., Wolter J., Hogea C., Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011, 9(9):761-774.
29. Dellicour S., Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007, 12(12):1409-1421.
30. Christensen H., Hickman M., Edmunds W.J., Trotter C.L. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31(23):2638-2646.
31. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13(5):416-425.
32. Hoiseth S.K., Murphy E., Andrew L., Vogel U., Frosch M., Hellenbrand W., et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 2013, 32(10):1096-1101.
33. Ala'aldeen D.A., Flint M., Oldfield N.J., Omer S.A., McNeil L.K., Jiang Q., et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010, 28(48):7667-7675.
34. Anderson A.S., Hao L., Jiang Q., Harris S.L., Jones T.R., Perez J.L., et al. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B. Dis Hum Vaccin Immunother 2012, 9(3).
35. Trotter C.L., Gay N.J. Analysis of longitudinal bacterial carriage studies accounting for sensitivity of swabbing: an application to Neisseria meningitidis. Epidemiol Infect 2003, 130(2):201-205.